Adaptimmune Therapeutics (ADAP)
(Delayed Data from NSDQ)
$1.04 USD
-0.01 (-0.95%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $1.03 -0.01 (-0.96%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMIndustry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 32% (81 out of 250)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 2.00 | 1.37 | 9.99 |
Current Quarter Estimate | -0.17 | 3.10 | 61.00 |
Year Ago Quarter Estimate | -0.20 | -4.81 | 54.84 |
Next Quarter Estimate | -0.12 | 3.85 | 63.00 |
Next Year Estimate | -0.63 | 24.86 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 61.90 | 17.20 | 15.67 |
Next Year | -162.50 | 9.30 | 11.34 |
Last 5 Years | NA | 0.90 | 8.10 |
Next 5 Years | NA | 22.00 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -6.44 |
Price/Book (MRQ) | 2.69 | 2.10 |
Price/Cash Flow (MRFY) | NA | 16.43 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -51.25% | -150.51% |
Return on Equity (TTM) | -116.80% | -61.16% |
Debt to Equity (MRQ) | 0.26 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.